Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
DR-0202 in Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Details : DR-0202 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Triple Negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 31, 2025
Lead Product(s) : SAR448501
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Sanofi
Deal Size : $1,900.0 million
Deal Type : Acquisition
Sanofi Completes Acquisition of DR-0201
Details : Sanofi acquired DR-0201, now named SAR448501, a targeted bispecific myeloid cell engager, has shown robust B-cell depletion in pre-clinical and early clinical studies.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $600.0 million
May 27, 2025
Lead Product(s) : SAR448501
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Sanofi
Deal Size : $1,900.0 million
Deal Type : Acquisition
Lead Product(s) : SAR448501
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Sanofi
Deal Size : $1,900.0 million
Deal Type : Acquisition
Sanofi to Acquire Dren Bio's Immunology Unit
Details : Sanofi acquires DR-0201 from Dren. It is CD20-directed bispecific antibody that targets & engages specific tissue-resident & trafficking myeloid cells to induce deep B-cell depletion.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $600.0 million
March 20, 2025
Lead Product(s) : SAR448501
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Sanofi
Deal Size : $1,900.0 million
Deal Type : Acquisition
Lead Product(s) : DR-01
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Subcutaneous DR-01 in Healthy Volunteers
Details : DR-01 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : DR-01
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DR-0201
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DR-0201 in Subjects With Autoimmune Diseases
Details : DR-0201 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 17, 2024
Lead Product(s) : DR-0201
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DR-01
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Details : DR-01 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alopecia Areata.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : DR-01
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Details : DR-0201 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : DR-0201
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DR-0201 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 23, 2023
Lead Product(s) : DR-0201
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DR-01
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Details : DR-01 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Large Granular Lymphocytic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 27, 2022
Lead Product(s) : DR-01
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : $1,025.0 million
Deal Type : Collaboration
Details : The strategic collaboration will focus on the discovery and development of therapeutic bispecific antibodies for selected oncology targets using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $25.0 million
January 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : $1,025.0 million
Deal Type : Collaboration